Endogenous inhibitor of GlyT1 that displays antipsychotic activity. Potentiates the action of glycine on the NMDA glycine binding site.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 89.09. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||11.22 mL||56.12 mL||112.25 mL|
|5 mM||2.24 mL||11.22 mL||22.45 mL|
|10 mM||1.12 mL||5.61 mL||11.22 mL|
|50 mM||0.22 mL||1.12 mL||2.24 mL|
References are publications that support the products' biological activity.
Tsai et al (2004) Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol.Psychiatry 55 452 PMID: 15023571
Singh and Singh (2011) Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 25 859 PMID: 21936588
If you know of a relevant reference for Sarcosine, please let us know.
View Related Products by Product Action
Keywords: Sarcosine, supplier, GlyT1, inhibitors, inhibits, Glycine, Transporters, Monoamine, Neurotransmitter, Glycine, Transporters, Glycine, Transporters, Tocris Bioscience
1 Citation for Sarcosine
Citations are publications that use Tocris products. Selected citations for Sarcosine include:
Yoshikawa et al (2012) Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur Urol 62 704 PMID: 22341128
Do you know of a great paper that uses Sarcosine from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.